Other purchasing groups, such as Vizient Inc., said they're trying to finalize purchasing contracts with Valeant after they weren't happy with the drugmaker's initial offers, which «did not
adequately meet the needs of the member providers we represent,» spokeswoman Angie Boliver said in an e-mail.